AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancer

AstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its import, sale, and distribution for an additional use. The drug will now be available as a first-line treatment for certain types of advanced breast cancer. This development expands treatment options for oncologists and patients facing HER2-positive breast cancer.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Wg9noPJ
via IFTTT